Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD4205 + carbamazepine
- Development stage
- Unknown
- Lead developer
- Dizal Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination of AZD4205, a selective oral JAK1 inhibitor being investigated for peripheral T-cell lymphoma, and carbamazepine, an established anticonvulsant medication. Carbamazepine is a CYP3A4 inducer that may potentially decrease the serum concentration of AZD4205, as carbamazepine is known to affect the metabolism of many drugs. AZD4205 has shown promising anti-tumor efficacy in relapsed/refractory peripheral T-cell lymphoma, while carbamazepine is primarily used to treat seizures, trigeminal neuralgia, and bipolar disorder.
- Brand names
- TegretolCarbatrolEpitolEquetro
02
Targets
JAK1 (Janus kinase 1)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on AZD4205 + carbamazepine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD4205 + carbamazepine.